SFU
HZNP

Stonehage Fleming (UK)’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Stonehage Fleming (UK)’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,304
Closed -$36K – 353
2014
Q2 		$36K Buy
+2,304
New +$32.9K 0.01% 191

Other funds holding HZNP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stonehage Fleming (UK)'s HZNP Position: Q3 2014 in Review

Stonehage Fleming (UK) sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2014, closing a stake of 2,304 shares — an estimated $36K sold.

Stonehage Fleming (UK) first reported a position in HZNP in Q2 2014 and held it in 1 quarter. The position peaked at $36K in Q2 2014. 120 funds tracked by Wall St. Rank hold HZNP as of Q3 2014.

  • Stonehage Fleming (UK) reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2014 after selling out during the quarter.
  • Stonehage Fleming (UK) sold 2,304 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2014, an estimated $36K.
  • Stonehage Fleming (UK) first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2014 and held it in 1 quarter.
  • Stonehage Fleming (UK)'s Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $36K in Q2 2014.
  • 120 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2014.

Based on Stonehage Fleming (UK)'s 13F filing for Q3 2014, filed 11 Oct 2019.